Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

First aim will be addressed in a cross-sectional randomized study. 20 healthy, lean and 20 obese individuals with type 2 diabetes (T2DM) will be exposed to food cues and with concomitant infusion of glucagon Like peptide-1 (GLP-1) receptor antagonist or saline, to assess the involvement of endogenous GLP-1, secreted in response to a meal. Measurements activation of CNS circuits involved in satiety and reward will be performed using blood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI).

The second aim will be addressed in cross-over randomized-controlled trial (RCT) in the T2DM patients only. Patients will be randomly assigned liraglutide vs insulin glargine treatment, during a treatment period of 12 weeks each with a 12-week washout period in between. The investigators will perform the same fMRI protocol.

The third aim will be addressed in a study with obese individuals who are scheduled for a gastric bypass surgery. The same protocol as for the first aim will be performed and this will be before and after the surgery in the same individuals.

Inclusion criteria

• For the healthy, lean individuals:
• Age 18-65 years
• Women: post menopausal (excluding possible menstruation cycle effects)
• Body-mass index (BMI) of <25 kg/m2,
• Stable bodyweight (<5% reported change during the previous 3 months).
• Normal fasting and 2h post load glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) (34)
• Right handed

For the obese T2DM individuals:

• Age 18-65 years
• Women: post menopausal (excluding possible menstruation cycle effects)
• BMI 25-40 kg/m2
• Stable bodyweight (<5% reported change during the previous 3 months).
• Diagnosed with T2DM > 3 months prior to screening
• HbA1C 6.5-8.5%
• Treatment with metformin at a stable dose for at least 3 months.
• Right handed

For the obese individuals scheduled for gastric bypass surgery:

• Age 18-65 years
• Women: preferably post menopausal (excluding possible menstruation cycle effects)
• Body-mass index (BMI) of >30 kg/m2,
• Stable bodyweight (<5% reported change during the previous 1 months).
• Normal or impaired fasting and 2h post load glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) (defined as glucose fasting < 7.1 mmol/l and after OGTT t=120min < 11.0 mmol/l) (39)
• Right handed

Exclusion criteria

• GLP-1 based therapies, thiazolidinediones, sulphonylurea or insulin within 3 months before screening
• Weight-lowering agents within 3 months before screening.
• Congestive heart failure (NYHA II-IV)
• Chronic renal failure (glomerular filtration rate < 60 mL/min/1.73m2 per Modification of Diet in Renal Disease (MDRD))
• Liver disease
• History of gastrointestinal disorders (including gastropareses, pancreatitis and cholelithiasis)
• Neurological illness
• Malignancy
• Other type of bariatric surgery (Redo-GBP, sleeve, distal GBP, adj banding, Scopinaro)
• History of major heart disease
• History of major renal disease
• Pregnancy or breast feeding
• Implantable devices
• Substance abuse
• Addiction
• Contra-indication for MRI, such as claustrophobia or pacemaker
• Any psychiatric illness; including eating disorders and depression
• Chronic use of centrally acting agents or glucocorticoids within 2 weeks immediately prior to screening.
• Use of cytostatic or immune modulatory agents
• History or known allergy for acetaminophen.
• History of allergy for insulin analog
• History of allergy for liraglutide
• Participation in other studies
• Individuals who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
• Individuals who are investigator site personnel, directly affiliated with the study, or are immediate family